通过树突细胞迁移介导的微生物驱动的抗瘤免疫力
Nina Yi-Tzu Lin1,2, Shota Fukuoka1, Shohei Koyama1,3
1Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
Nature
|July 14, 2025
概括
一种新的肠道细菌Hominenteromicrobium YB328可以增强抗癌免疫疗法. 这种细菌通过激活树突细胞来增强CD8+T细胞的反应,改善了小鼠模型和人类癌症患者的编程细胞死亡-1 (PD-1) 阻断效果.
科学领域:
- 免疫学
- 微生物学
- 癌症学
背景情况:
- 肠道微生物群在免疫检查点阻断的有效性是公认的,但在机理上不清楚.
- 编程细胞死亡-1 (PD-1) 阻断是一种关键的癌症免疫疗法,但反应率各不相同.
研究的目的:
- 阐明肠道微生物群如何影响PD-1阻断的有效性.
- 确定可以增强抗瘤免疫反应的特定细菌菌株.
主要方法:
- 从患者便中分离和描述一种新型细菌菌株,Hominenteromicrobium YB328.
- 使用小鼠癌症模型进行体内研究,以评估YB328对PD-1阻断的影响.
- 对免疫细胞群 (CD8+ T细胞,树突细胞) 和它们在瘤和淋巴组织中的相互作用进行分析.
- 人类癌症患者中YB328丰度与临床反应和免疫细胞透的相关性.
主要成果:
- 在小鼠模型中,Hominenteromicrobium YB328显著增强了PD-1阻断的抗瘤功效.
- 通过CD103+CD11b-传统树突细胞 (cDC) 激活了YB328的瘤特异性CD8+T细胞.
- 由YB328刺激的cDC从肠道迁移到瘤微环境,延长T细胞的参与.
- 人类癌症患者中YB328度的增加与增加的cDC透和有利的PD-1阻断反应相关.
结论:
- 人体内微生物YB328是一种强大的抗瘤免疫调节剂,增强了PD-1阻断的有效性.
- 该机制涉及YB328驱动的cDC成熟和迁移,导致瘤特异性的CD8+ T细胞反应增加.
- 向或补充YB328是一种改善癌症免疫治疗结果的潜在策略.
相关概念视频
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
01:27Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664